2 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
Follow Biliary Tract Cancers: new trials by email Literature Review of Biliary Tract Cancers trials Research Report on Biliary Tract Cancers
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC) mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab - Biliary Tract Cancers | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 25 | 2025-05-27 | 2026-05-08 |
| Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 ABBV-400, Itraconazole (ITZ), Bevacizumab - Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | AbbVie | 325 | 2023-11-09 | 2026-10-14 |
Biliary Tract Neoplasms (2) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Esophageal Squamous Cell Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
Biliary Tract Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Adenocarcinoma (1) · Breast Diseases (1) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Squamous Cell (1) · Esophageal Diseases (1) · Esophageal Neoplasms (1) · Gastrointestinal Diseases (1)
Bevacizumab (1) · Itraconazole (1) · Peptides (1) · durvalumab (1) · poly ICLC (1) · tremelimumab (1)
AbbVie (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (2) · Australia (1) · Israel (1) · Japan (1) · Puerto Rico (1) · South Korea (1) · Spain (1) · Taiwan (1)
2023 (1)